UPDATE: J.P. Morgan Initiates Coverage on Isis Pharmaceuticals, Awaiting Better Entry Point

In a report published Friday, J.P. Morgan analyst Cory Kasimov initiated coverage on Isis Pharmaceuticals ISIS with a Neutral rating and $37.00 price target. In the report, J.P. Morgan noted, “We are initiating coverage of Isis Pharmaceuticals with a Neutral rating. The company is well positioned, in our view, with a validated technology platform and attractive blend of proprietary and partnered products. Three pipeline programs in particular – ISIS-APOCIIIRx, ISIS-SMNRx, and ISIS-TTRRx – have generated exciting early data and possess multi-billion-dollar revenue potential. However, we would look for a better entry point, as we believe much of the pipeline's impressive recent progress is reflected in the current valuation (shares up +243% YTD vs. S&P +18%).” Isis Pharmaceuticals closed on Thursday at $35.83.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationAnalyst RatingsCory KasimovJ.P. Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!